Cargando…

Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions

Novel 2019 coronavirus has created havoc across the globe since its emergence in December 2019 in Wuhan, China, and fast spreading potential. While we were able to identify the causative agent within a few days of the disease outbreak, several questions still remain unanswered. In this review, we di...

Descripción completa

Detalles Bibliográficos
Autores principales: Jogalekar, Manasi P, Veerabathini, Anurag, Gangadaran, Prakash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327953/
https://www.ncbi.nlm.nih.gov/pubmed/32306751
http://dx.doi.org/10.1177/1535370220920540
_version_ 1783552659151650816
author Jogalekar, Manasi P
Veerabathini, Anurag
Gangadaran, Prakash
author_facet Jogalekar, Manasi P
Veerabathini, Anurag
Gangadaran, Prakash
author_sort Jogalekar, Manasi P
collection PubMed
description Novel 2019 coronavirus has created havoc across the globe since its emergence in December 2019 in Wuhan, China, and fast spreading potential. While we were able to identify the causative agent within a few days of the disease outbreak, several questions still remain unanswered. In this review, we discuss the extent of virus spread, current statistics, SARS-CoV-2 genome organization, comparison between the novel coronavirus and causative agents involved in previous outbreaks, ongoing clinical trials and myths associated with the virus. Lastly, we provide insights into the future perspectives which could prove useful for the scientific community as they work on finding the cure against the disease. IMPACT STATEMENT: Early availability of the sequence, the genetic material of SARS-CoV-2 (the virus that causes COVID-19), has prompted efforts towards identifying a safe and effective vaccine in the current public health emergency. To that end, understanding the pathophysiology of disease is crucial for scientists around the world. Since conventional vaccine development and manufacturing may take several years, it is important to think about alternative strategies that we could use to mitigate imminent catastrophe. We hope that this article will open up new avenues and provide insights that could potentially save hundreds of lives affected by COVID-19.
format Online
Article
Text
id pubmed-7327953
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-73279532020-07-09 Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions Jogalekar, Manasi P Veerabathini, Anurag Gangadaran, Prakash Exp Biol Med (Maywood) Minireview Novel 2019 coronavirus has created havoc across the globe since its emergence in December 2019 in Wuhan, China, and fast spreading potential. While we were able to identify the causative agent within a few days of the disease outbreak, several questions still remain unanswered. In this review, we discuss the extent of virus spread, current statistics, SARS-CoV-2 genome organization, comparison between the novel coronavirus and causative agents involved in previous outbreaks, ongoing clinical trials and myths associated with the virus. Lastly, we provide insights into the future perspectives which could prove useful for the scientific community as they work on finding the cure against the disease. IMPACT STATEMENT: Early availability of the sequence, the genetic material of SARS-CoV-2 (the virus that causes COVID-19), has prompted efforts towards identifying a safe and effective vaccine in the current public health emergency. To that end, understanding the pathophysiology of disease is crucial for scientists around the world. Since conventional vaccine development and manufacturing may take several years, it is important to think about alternative strategies that we could use to mitigate imminent catastrophe. We hope that this article will open up new avenues and provide insights that could potentially save hundreds of lives affected by COVID-19. SAGE Publications 2020-04-19 2020-06 /pmc/articles/PMC7327953/ /pubmed/32306751 http://dx.doi.org/10.1177/1535370220920540 Text en © 2020 by the Society for Experimental Biology and Medicine https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Minireview
Jogalekar, Manasi P
Veerabathini, Anurag
Gangadaran, Prakash
Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions
title Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions
title_full Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions
title_fullStr Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions
title_full_unstemmed Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions
title_short Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions
title_sort novel 2019 coronavirus: genome structure, clinical trials, and outstanding questions
topic Minireview
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327953/
https://www.ncbi.nlm.nih.gov/pubmed/32306751
http://dx.doi.org/10.1177/1535370220920540
work_keys_str_mv AT jogalekarmanasip novel2019coronavirusgenomestructureclinicaltrialsandoutstandingquestions
AT veerabathinianurag novel2019coronavirusgenomestructureclinicaltrialsandoutstandingquestions
AT gangadaranprakash novel2019coronavirusgenomestructureclinicaltrialsandoutstandingquestions